Illumina, Inc. (ILMN) Shares Sold by IFP Advisors Inc
IFP Advisors Inc reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 40.8% during the second quarter, Holdings Channel reports. The fund owned 3,951 shares of the life sciences company’s stock after selling 2,728 shares during the period. IFP Advisors Inc’s holdings in Illumina were worth $686,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its position in Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after buying an additional 1,800 shares in the last quarter. State of Tennessee Treasury Department increased its position in Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock worth $16,697,000 after buying an additional 7,040 shares in the last quarter. Bank of Nova Scotia increased its position in Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after buying an additional 62,612 shares in the last quarter. Aberdeen Asset Management PLC UK increased its position in Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock worth $4,775,000 after buying an additional 2,158 shares in the last quarter. Finally, Eastern Bank acquired a new position in Illumina during the first quarter worth $256,000. Institutional investors own 93.81% of the company’s stock.
Shares of Illumina, Inc. (ILMN) opened at 194.65 on Friday. The firm has a market capitalization of $28.42 billion, a price-to-earnings ratio of 39.05 and a beta of 0.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95. The firm has a 50-day moving average of $179.31 and a 200 day moving average of $173.49.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The company had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.86 earnings per share. Analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.
A number of research firms have recently weighed in on ILMN. Barclays PLC restated an “equal weight” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday. Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target on the stock in a report on Wednesday. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $215.00 in a report on Monday. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday. Finally, Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $177.01.
In other news, Director Frances Arnold sold 825 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $174.77, for a total value of $144,185.25. Following the transaction, the director now directly owns 8,816 shares of the company’s stock, valued at $1,540,772.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the transaction, the senior vice president now directly owns 10,791 shares in the company, valued at $1,993,637.25. The disclosure for this sale can be found here. Insiders sold 134,010 shares of company stock worth $23,946,015 over the last three months. Insiders own 1.60% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.